Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model

Author's Avatar
May 17, 2021

Suicide Prevention Company Rapidly Expanding Pipeline on Immunotherapy of Psychiatric Conditions

PR Newswire